Skip to main content
Erschienen in: Familial Cancer 4/2019

04.07.2019 | Original Article

Hereditary diffuse gastric cancer: cancer risk and the personal cost of preventive surgery

verfasst von: P. Kaurah, A. Talhouk, A. MacMillan, I. Lewis, K. Chelcun-Schreiber, S. S. Yoon, D. Huntsman

Erschienen in: Familial Cancer | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Germline CDH1 mutation carriers are at risk for early-onset diffuse gastric cancer (DGC) and female carriers have an additional risk of lobular breast cancer. The reported literature GC risk of 70% has led to the recommendation for germline mutation carriers to undergo prophylactic total gastrectomy (PTG). The objective of this research was to examine post-surgical clinical outcomes and to identify which of the domains/symptoms from the European Organisation for Research and Treatment of Cancer QOL Questionnaire (EORTC QLQ-C30) were determinants of overall quality of life (QOL) in individuals undergoing PTG. Participants were recruited through multiple sources. Postsurgical clinical outcomes were obtained from hospital records. Participants completed validated questionnaires measuring generic and condition specific QOL (PROMIS, EORTC and SF 36v.II) at a single point in time. The mean QOL in this cohort was 70.6 (SD = 25.6), which is better than reference values from the general populations in USA and Canada Role and social function plus the symptoms anxiety, pain, taste, dyspnea and diarrhea were significant predictor variables for QOL (p < 0.05). Although this study reveals good overall QOL for individuals after PTG, attention should be given to managing symptoms as part of long term care to further enhance QOL. The function/symptom scores were associated with worse overall health and global health status and thus may mark a real need for more attentive post-surgical care.
Literatur
1.
Zurück zum Zitat Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K, Zogopoulos G, Santos TA, Claro I, Carvalho J, Nielsen C, Padilla S, Lum A, Talhouk A, Baker-Lange K, Richardson S, Lewis I, Lindor NM, Pennell E, MacMillan A, Fernandez B, Keller G, Lynch H, Shah SP, Guilford P, Gallinger S, Corso G, Roviello F, Caldas C, Oliveira C, Pharoah PD, Huntsman DGDG (2015) Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol 1(1):23–32. https://doi.org/10.1001/jamaoncol.2014.168 CrossRefPubMed Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K, Zogopoulos G, Santos TA, Claro I, Carvalho J, Nielsen C, Padilla S, Lum A, Talhouk A, Baker-Lange K, Richardson S, Lewis I, Lindor NM, Pennell E, MacMillan A, Fernandez B, Keller G, Lynch H, Shah SP, Guilford P, Gallinger S, Corso G, Roviello F, Caldas C, Oliveira C, Pharoah PD, Huntsman DGDG (2015) Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol 1(1):23–32. https://​doi.​org/​10.​1001/​jamaoncol.​2014.​168 CrossRefPubMed
2.
Zurück zum Zitat van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, Bardram L, Benusiglio PR, Bisseling TM, Blair V, Bleiker E, Boussioutas A, Cats A, Coit D, DeGregorio L, Figueiredo J, Ford JM, Heijkoop E, Hermens R, Humar B, Kaurah P, Keller G, Lai J, Ligtenberg MJ, O’Donovan M, Oliveira C, Pinheiro H, Ragunath K, Rasenberg E, Richardson S, Roviello F, Schackert H, Seruca R, Taylor A, Ter Huurne A, Tischkowitz M, Joe ST, van Dijck B, van Grieken NC, van Hillegersberg R, van Sandick JW, Vehof R, van Krieken JH, Fitzgerald RC (2015) Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 52(6):361–374. https://doi.org/10.1136/jmedgenet-2015-103094 (Epub 2015 May 15) CrossRefPubMedPubMedCentral van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, Bardram L, Benusiglio PR, Bisseling TM, Blair V, Bleiker E, Boussioutas A, Cats A, Coit D, DeGregorio L, Figueiredo J, Ford JM, Heijkoop E, Hermens R, Humar B, Kaurah P, Keller G, Lai J, Ligtenberg MJ, O’Donovan M, Oliveira C, Pinheiro H, Ragunath K, Rasenberg E, Richardson S, Roviello F, Schackert H, Seruca R, Taylor A, Ter Huurne A, Tischkowitz M, Joe ST, van Dijck B, van Grieken NC, van Hillegersberg R, van Sandick JW, Vehof R, van Krieken JH, Fitzgerald RC (2015) Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 52(6):361–374. https://​doi.​org/​10.​1136/​jmedgenet-2015-103094 (Epub 2015 May 15) CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, Maung R, Seruca R, Jackson CE, Caldas C (2001) Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 344(25):1904–1909CrossRef Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, Maung R, Seruca R, Jackson CE, Caldas C (2001) Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 344(25):1904–1909CrossRef
4.
Zurück zum Zitat Lewis FR, Mellinger JD, Hayashi A, Lorelli D, Monaghan KG, Carneiro F, Huntsman DG, Jackson CE, Caldas C (2001) Prophylactic total gastrectomy for familial gastric cancer. Surgery 130(4):612–617 (discussion 617-9) CrossRef Lewis FR, Mellinger JD, Hayashi A, Lorelli D, Monaghan KG, Carneiro F, Huntsman DG, Jackson CE, Caldas C (2001) Prophylactic total gastrectomy for familial gastric cancer. Surgery 130(4):612–617 (discussion 617-9) CrossRef
5.
Zurück zum Zitat Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ, Donohue JH (2001) Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer 92(1):181–187CrossRef Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ, Donohue JH (2001) Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer 92(1):181–187CrossRef
6.
Zurück zum Zitat Newman EA, Mulholland MW (2006) Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome. J Am Coll Surg 202(4):612–617CrossRef Newman EA, Mulholland MW (2006) Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome. J Am Coll Surg 202(4):612–617CrossRef
7.
Zurück zum Zitat Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kurian AW, Ford JM (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245(6):873CrossRef Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kurian AW, Ford JM (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245(6):873CrossRef
8.
Zurück zum Zitat Hebbard PC, Macmillan A, Huntsman D, Kaurah P, Carneiro F, Wen X, Kwan A, Boone D, Bursey F, Green J, Fernandez B, Fontaine D, Wirtzfeld DA (2009) Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol 16(7):1890–1895CrossRef Hebbard PC, Macmillan A, Huntsman D, Kaurah P, Carneiro F, Wen X, Kwan A, Boone D, Bursey F, Green J, Fernandez B, Fontaine D, Wirtzfeld DA (2009) Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol 16(7):1890–1895CrossRef
10.
Zurück zum Zitat Pandalai PK, Lauwers GY, Chung DC, Patel D, Yoon SS (2011) Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery 149(3):347–355CrossRef Pandalai PK, Lauwers GY, Chung DC, Patel D, Yoon SS (2011) Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery 149(3):347–355CrossRef
12.
Zurück zum Zitat Li J, McBean E, Li X, Berho M, Szomstein S, Rosenthal RJ (2013) Laparoscopic prophylactic total gastrectomy with linear stapler side-to-side esophagojejunal anastomosis for hereditary diffuse gastric cancer syndrome in 2 siblings. Surg Laparosc Endosc Percutaneous Tech 23(3):e124–e126. https://doi.org/10.1097/SLE.0b013e3182773e38 CrossRef Li J, McBean E, Li X, Berho M, Szomstein S, Rosenthal RJ (2013) Laparoscopic prophylactic total gastrectomy with linear stapler side-to-side esophagojejunal anastomosis for hereditary diffuse gastric cancer syndrome in 2 siblings. Surg Laparosc Endosc Percutaneous Tech 23(3):e124–e126. https://​doi.​org/​10.​1097/​SLE.​0b013e3182773e38​ CrossRef
14.
Zurück zum Zitat Worster E, Liu X, Richardson S, Hardwick RH, Dwerryhouse S, Caldas C, Fitzgerald RC (2014) The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study. Ann Surg 260(1):87–93CrossRef Worster E, Liu X, Richardson S, Hardwick RH, Dwerryhouse S, Caldas C, Fitzgerald RC (2014) The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study. Ann Surg 260(1):87–93CrossRef
15.
Zurück zum Zitat Muir J, Aronson M, Esplen MJ, Pollett A, Swallow CJ (2016) Prophylactic total gastrectomy: a prospective cohort study of long-term impact on quality of life. J Gastrointest Surg 20(12):1950–1958 (Epub 2016 Oct 17) CrossRef Muir J, Aronson M, Esplen MJ, Pollett A, Swallow CJ (2016) Prophylactic total gastrectomy: a prospective cohort study of long-term impact on quality of life. J Gastrointest Surg 20(12):1950–1958 (Epub 2016 Oct 17) CrossRef
16.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRef
17.
Zurück zum Zitat Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O et al (2004) Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 40(15):2260–2268CrossRef Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O et al (2004) Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 40(15):2260–2268CrossRef
18.
Zurück zum Zitat Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D, PROMIS Cooperative Group (2011) Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger. Assessment 18(3):263–283CrossRef Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D, PROMIS Cooperative Group (2011) Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger. Assessment 18(3):263–283CrossRef
19.
Zurück zum Zitat Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) EORTC QLQ-C30 Scoring Manual Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) EORTC QLQ-C30 Scoring Manual
20.
Zurück zum Zitat Nolte S, Liegl G, Petersen MA, Aaronson NK, Costantini A, Fayers PM, Groenvold M, Holzner B, Johnson CD, Kemmler G, Tomaszewski KA, Waldmann A, Young TE, Rose M, EORTC Quality of Life Group (2019) General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur J Cancer 107:153–163CrossRef Nolte S, Liegl G, Petersen MA, Aaronson NK, Costantini A, Fayers PM, Groenvold M, Holzner B, Johnson CD, Kemmler G, Tomaszewski KA, Waldmann A, Young TE, Rose M, EORTC Quality of Life Group (2019) General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur J Cancer 107:153–163CrossRef
21.
Zurück zum Zitat Ferrans CE, Powers MJ (1993) Quality of life of hemodialysis patients. Anna J 20(5):575–581 (discussion 582) PubMed Ferrans CE, Powers MJ (1993) Quality of life of hemodialysis patients. Anna J 20(5):575–581 (discussion 582) PubMed
24.
Zurück zum Zitat Diaz De Liano A, Oteiza Martinez F, Ciga MA, Aizcorbe M, Cobo F, Trujillo R (2003) Impact of surgical procedure for gastric cancer on quality of life. Br J Surg 90(1):91–94CrossRef Diaz De Liano A, Oteiza Martinez F, Ciga MA, Aizcorbe M, Cobo F, Trujillo R (2003) Impact of surgical procedure for gastric cancer on quality of life. Br J Surg 90(1):91–94CrossRef
25.
Zurück zum Zitat Rocha JP, Gullo I, Wen X, Devezas V, Baptista M, Oliveira C, Carneiro F (2018) Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management. Histopathology 73(6):878–886 (Epub 2018 Oct 9. Review) CrossRef Rocha JP, Gullo I, Wen X, Devezas V, Baptista M, Oliveira C, Carneiro F (2018) Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management. Histopathology 73(6):878–886 (Epub 2018 Oct 9. Review) CrossRef
26.
Zurück zum Zitat Tichansky DS, Boughter JD Jr, Madan AK (2006) Taste change after laparoscopic Roux-en-Y gastric bypass and laparoscopic adjustable gastric band. Surg Obes Relat Dis 2:440–444CrossRef Tichansky DS, Boughter JD Jr, Madan AK (2006) Taste change after laparoscopic Roux-en-Y gastric bypass and laparoscopic adjustable gastric band. Surg Obes Relat Dis 2:440–444CrossRef
27.
Zurück zum Zitat Harris AM, Griffin SM (2003) Postoperative taste and smell deficit after upper gastrointestinal cancer surgery—an unreported complication. J Surg Oncol 82:147–150CrossRef Harris AM, Griffin SM (2003) Postoperative taste and smell deficit after upper gastrointestinal cancer surgery—an unreported complication. J Surg Oncol 82:147–150CrossRef
28.
Zurück zum Zitat Carey S, Laws R, Ferrie S, Young J, Allman-Farinelli M (2013) Struggling with food and eating—life after major upper gastrointestinal surgery. Support Care Cancer 21:2749–2757CrossRef Carey S, Laws R, Ferrie S, Young J, Allman-Farinelli M (2013) Struggling with food and eating—life after major upper gastrointestinal surgery. Support Care Cancer 21:2749–2757CrossRef
30.
Zurück zum Zitat Maeda T, Onuoha FN, Munakata T (2006) The effect of postoperative symptom experience, and personality and psychosocial factors on depression among postgastrectomy patients in Japan. Gastroenterol Nurs 29(6):437–444CrossRef Maeda T, Onuoha FN, Munakata T (2006) The effect of postoperative symptom experience, and personality and psychosocial factors on depression among postgastrectomy patients in Japan. Gastroenterol Nurs 29(6):437–444CrossRef
32.
Zurück zum Zitat Brintzenhofe-Szoc KM, Levin TT, Li Y, Kissane DW, Zabora JR (2009) Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics 50:383–391CrossRef Brintzenhofe-Szoc KM, Levin TT, Li Y, Kissane DW, Zabora JR (2009) Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics 50:383–391CrossRef
33.
Zurück zum Zitat Stark D, Kiely M, Smith A, Velikova G, House A, Selby P (2002) Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 20(14):3137–3148CrossRef Stark D, Kiely M, Smith A, Velikova G, House A, Selby P (2002) Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 20(14):3137–3148CrossRef
34.
Zurück zum Zitat Kim AR, Cho J, Hsu YJ, Choi MG, Noh JH, Sohn TS, Bae JM, Yun YH, Kim S (2012) Changes of quality of life in gastric cancer patients after curative resection: a longitudinal cohort study in Korea. Ann Surg 256(6):1008–1013CrossRef Kim AR, Cho J, Hsu YJ, Choi MG, Noh JH, Sohn TS, Bae JM, Yun YH, Kim S (2012) Changes of quality of life in gastric cancer patients after curative resection: a longitudinal cohort study in Korea. Ann Surg 256(6):1008–1013CrossRef
35.
Zurück zum Zitat Kobayashi D, Kodera Y, Fujiwara M, Koike M, Nakayama G, Nakao A (2011) Assessment of quality of life after gastrectomy using EORTC QLQ-C30 and STO22. World J Surg 35(2):357–364CrossRef Kobayashi D, Kodera Y, Fujiwara M, Koike M, Nakayama G, Nakao A (2011) Assessment of quality of life after gastrectomy using EORTC QLQ-C30 and STO22. World J Surg 35(2):357–364CrossRef
37.
Zurück zum Zitat Wu CW, Chiou JM, Ko FS, Lo SS, Chen JH, Lui WY, Whang-Peng J (2008) Quality of life after curative gastrectomy for gastric cancer in a randomised controlled trial. Br J Cancer 98(1):54–59CrossRef Wu CW, Chiou JM, Ko FS, Lo SS, Chen JH, Lui WY, Whang-Peng J (2008) Quality of life after curative gastrectomy for gastric cancer in a randomised controlled trial. Br J Cancer 98(1):54–59CrossRef
39.
Zurück zum Zitat Cohen S, Wills TA (1985) Stress, social support, and the buffering hypothesis. Psychol Bull 98(2):310CrossRef Cohen S, Wills TA (1985) Stress, social support, and the buffering hypothesis. Psychol Bull 98(2):310CrossRef
Metadaten
Titel
Hereditary diffuse gastric cancer: cancer risk and the personal cost of preventive surgery
verfasst von
P. Kaurah
A. Talhouk
A. MacMillan
I. Lewis
K. Chelcun-Schreiber
S. S. Yoon
D. Huntsman
Publikationsdatum
04.07.2019
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2019
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-019-00133-9

Weitere Artikel der Ausgabe 4/2019

Familial Cancer 4/2019 Zur Ausgabe

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.